mirabegron 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta3-adrenoreceptor agonists 4382 223673-61-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • YM178
  • myrbetriq
  • mirabegron
a beta-3 adrenergic agonist, relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 AR which increases bladder capacity
  • Molecular weight: 396.51
  • Formula: C21H24N4O2S
  • CLOGP: 1.32
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 100.27
  • ALOGS: -4.98
  • ROTB: 9

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 23.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.29 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 28, 2012 FDA APGDI

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 160.75 13.12 104 17108 26086 50561826
Intentional product misuse 138.79 13.12 120 17092 46614 50541298
Blood pressure increased 129.82 13.12 191 17021 132941 50454971
Urinary tract infection 125.32 13.12 251 16961 223769 50364143
Blepharospasm 79.85 13.12 32 17180 2916 50584996
Urinary incontinence 78.81 13.12 70 17142 28138 50559774
Fall 77.63 13.12 270 16942 334662 50253250
Memory impairment 70.33 13.12 109 17103 79251 50508661
Hypertension 68.03 13.12 191 17021 211012 50376900
Taste disorder 63.55 13.12 38 17174 8286 50579626
Drug dispensed to wrong patient 61.00 13.12 14 17198 181 50587731
Toxicity to various agents 59.87 13.12 3 17209 212496 50375416
Residual urine volume increased 58.56 13.12 10 17202 21 50587891
Dry mouth 55.21 13.12 81 17131 56097 50531815
Bladder pain 48.34 13.12 19 17193 1645 50586267
Multiple sclerosis relapse 48.20 13.12 66 17146 42898 50545014
Multiple sclerosis 47.82 13.12 46 17166 20447 50567465
Off label use 44.26 13.12 294 16918 474132 50113780
Dermatitis atopic 42.87 13.12 22 17190 3564 50584348
Kidney infection 39.86 13.12 40 17172 18706 50569206
Contraindicated product administered 39.25 13.12 3 17209 148955 50438957
Scleral discolouration 38.54 13.12 11 17201 351 50587561
Maternal exposure during pregnancy 37.49 13.12 5 17207 159773 50428139
Epilepsy 36.92 13.12 41 17171 21526 50566386
Cystitis 36.40 13.12 59 17153 44505 50543407
Pollakiuria 33.57 13.12 41 17171 23810 50564102
Palpitations 32.86 13.12 88 17124 94418 50493494
Muscular weakness 32.56 13.12 88 17124 94925 50492987
Anxiety disorder 31.28 13.12 18 17194 3655 50584257
Treatment failure 30.68 13.12 5 17207 137632 50450280
Sinonasal obstruction 30.41 13.12 8 17204 187 50587725
On and off phenomenon 30.36 13.12 13 17199 1399 50586513
Migraine 29.15 13.12 73 17139 75207 50512705
Lip disorder 28.82 13.12 12 17200 1205 50586707
Infusion related reaction 28.51 13.12 11 17201 169546 50418366
Rheumatoid arthritis 28.18 13.12 17 17195 202533 50385379
Micturition urgency 28.17 13.12 23 17189 8241 50579671
Vitamin D deficiency 27.36 13.12 26 17186 11376 50576536
Dementia 26.68 13.12 30 17182 15967 50571945
Glossodynia 26.20 13.12 4 17208 115565 50472347
Schizophrenia 26.09 13.12 21 17191 7376 50580536
Exposure during pregnancy 25.66 13.12 5 17207 121010 50466902
Therapeutic product effect decreased 24.28 13.12 8 17204 136042 50451870
Gait disturbance 24.11 13.12 108 17104 149897 50438015
Intercepted medication error 24 13.12 8 17204 431 50587481
Feeling drunk 23.61 13.12 15 17197 3638 50584274
Idiopathic orbital inflammation 23.55 13.12 6 17206 123 50587789
Nocturia 23.51 13.12 19 17193 6711 50581201
Anal incontinence 23.48 13.12 24 17188 11466 50576446
Sputum retention 23.32 13.12 8 17204 471 50587441
Antineutrophil cytoplasmic antibody increased 22.78 13.12 5 17207 52 50587860
Haemorrhoids 22.47 13.12 30 17182 19023 50568889
Dysuria 22.27 13.12 37 17175 28467 50559445
Systemic lupus erythematosus 22.22 13.12 10 17202 140612 50447300
Balance disorder 21.83 13.12 63 17149 70527 50517385
Dizziness 21.76 13.12 196 17016 346173 50241739
Bladder disorder 21.62 13.12 19 17193 7524 50580388
Hand deformity 21.54 13.12 4 17208 100195 50487717
Drug hypersensitivity 21.09 13.12 33 17179 250977 50336935
Dyspepsia 20.89 13.12 64 17148 74033 50513879
Synovitis 20.87 13.12 8 17204 123857 50464055
Metastatic neoplasm 20.81 13.12 14 17198 3740 50584172
Swelling 20.34 13.12 23 17189 200849 50387063
Constipation 20.27 13.12 120 17092 185588 50402324
Disease progression 20.24 13.12 4 17208 95862 50492050
Arrhythmia 19.48 13.12 38 17174 33094 50554818
Lung neoplasm malignant 19.22 13.12 25 17187 15459 50572453
Hypertensive crisis 19.14 13.12 23 17189 13131 50574781
Vascular stenosis 19.11 13.12 6 17206 267 50587645
Pharyngeal mass 19.08 13.12 6 17206 268 50587644
Dyskinesia 18.93 13.12 34 17178 27827 50560085
Urinary tract disorder 18.51 13.12 11 17201 2369 50585543
Hypoaesthesia 18.50 13.12 89 17123 127168 50460744
Conjunctival discolouration 18.28 13.12 4 17208 41 50587871
Paraesthesia 18.14 13.12 85 17127 120158 50467754
Lip swelling 17.86 13.12 31 17181 24705 50563207
Product blister packaging issue 17.69 13.12 5 17207 154 50587758
Neutropenia 17.21 13.12 15 17197 147950 50439962
Insomnia 17.19 13.12 110 17102 174755 50413157
Hypothyroidism 16.37 13.12 36 17176 34089 50553823
Hyperventilation 16.26 13.12 14 17198 5395 50582517
Thrombocytopenia 16.02 13.12 12 17200 127661 50460251
Persistent genital arousal disorder 15.42 13.12 5 17207 247 50587665
Muscle atrophy 14.77 13.12 14 17198 6107 50581805
Wound 14.53 13.12 9 17203 105785 50482127
VIIth nerve injury 14.38 13.12 4 17208 116 50587796
Abdominal pain upper 14.31 13.12 98 17114 159211 50428701
Neurogenic bladder 14.29 13.12 10 17202 2847 50585065
Open fracture 14.19 13.12 5 17207 319 50587593
Angina pectoris 14.15 13.12 29 17183 26159 50561753
Lymphocyte count decreased 14.06 13.12 29 17183 26278 50561634
Hyperlipidaemia 14.06 13.12 23 17189 17467 50570445
Product packaging quantity issue 14 13.12 7 17205 1073 50586839
Arthropathy 13.98 13.12 20 17192 157886 50430026
Catheter site injury 13.97 13.12 4 17208 129 50587783
Febrile neutropenia 13.85 13.12 8 17204 97659 50490253
Discomfort 13.84 13.12 10 17202 108370 50479542
Sleep apnoea syndrome 13.58 13.12 27 17185 23841 50564071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 162.14 17.18 101 7440 31797 29535189
Hallucination 124.73 17.18 98 7443 44614 29522372
Intentional product misuse 63.93 17.18 60 7481 34601 29532385
Fall 54.13 17.18 131 7410 177047 29389939
Nocturia 46.28 17.18 28 7513 8334 29558652
Platypnoea 45.33 17.18 8 7533 32 29566954
Confusional state 44.98 17.18 100 7441 127777 29439209
Urinary tract infection 43.32 17.18 71 7470 72283 29494703
Phaeochromocytoma malignant 39.80 17.18 8 7533 72 29566914
Delusion 38.78 17.18 28 7513 11188 29555798
Blood pressure increased 37.05 17.18 67 7474 73736 29493250
Micturition urgency 35.72 17.18 20 7521 5153 29561833
Urinary incontinence 35.20 17.18 31 7510 16450 29550536
Drug ineffective 31.41 17.18 178 7363 362992 29203994
Dementia 29.13 17.18 24 7517 11634 29555352
Arrhythmia 27.78 17.18 37 7504 31276 29535710
Gait disturbance 26.45 17.18 58 7483 73291 29493695
Bone marrow oedema 25.29 17.18 8 7533 489 29566497
Blood pressure systolic increased 25.14 17.18 26 7515 16819 29550167
Oesophageal dilatation 24.58 17.18 6 7535 139 29566847
Spinal cord haemorrhage 24.29 17.18 7 7534 311 29566675
Hypertensive crisis 23.56 17.18 18 7523 7830 29559156
Constipation 23.36 17.18 73 7468 114087 29452899
Pollakiuria 23.27 17.18 25 7516 16891 29550095
Extradural haematoma 22.45 17.18 9 7532 1097 29565889
Prescribed underdose 21.51 17.18 17 7524 7769 29559217
Off label use 21.21 17.18 140 7401 300660 29266326
On and off phenomenon 20.62 17.18 10 7531 1918 29565068
Orthostatic hypotension 20.47 17.18 27 7514 22602 29544384
Dropped head syndrome 19.82 17.18 5 7536 133 29566853
Toxicity to various agents 19.48 17.18 10 7531 173651 29393335
Dysuria 19.11 17.18 26 7515 22414 29544572
Cystitis interstitial 19.09 17.18 5 7536 155 29566831
Dyskinesia oesophageal 18.49 17.18 4 7537 53 29566933
Perineal pain 18.11 17.18 7 7534 775 29566211
Cerebral infarction 17.21 17.18 26 7515 24649 29542337

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 181.37 13.14 138 19890 49063 64429641
Urinary tract infection 125.52 13.14 243 19785 231353 64247351
Fall 113.11 13.14 334 19694 416492 64062212
Urinary incontinence 88.45 13.14 80 19948 36071 64442633
Blood pressure increased 73.35 13.14 164 19864 172388 64306316
Hallucination 72.96 13.14 101 19927 72687 64406017
Toxicity to various agents 72.03 13.14 13 20015 363500 64115204
Blepharospasm 68.36 13.14 29 19999 3346 64475358
Memory impairment 63.17 13.14 103 19925 85579 64393125
Taste disorder 62.35 13.14 38 19990 9395 64469309
Bladder pain 55.94 13.14 21 20007 1760 64476944
Residual urine volume increased 54.51 13.14 9 20019 16 64478688
Hypertension 53.96 13.14 190 19838 259071 64219633
Drug dispensed to wrong patient 53.10 13.14 14 20014 363 64478341
Intentional product misuse 49.39 13.14 84 19944 72211 64406493
Gait disturbance 47.47 13.14 139 19889 172016 64306688
On and off phenomenon 45.62 13.14 20 20008 2499 64476205
Cystitis 43.92 13.14 60 19968 42615 64436089
Platypnoea 43.76 13.14 8 20020 32 64478672
Pollakiuria 43.00 13.14 51 19977 31479 64447225
Micturition urgency 42.47 13.14 31 19997 10328 64468376
Dry mouth 42.32 13.14 71 19957 60347 64418357
Multiple sclerosis relapse 41.08 13.14 57 19971 41078 64437626
Kidney infection 40.75 13.14 38 19990 17800 64460904
Phaeochromocytoma malignant 38.22 13.14 8 20020 72 64478632
Confusional state 36.39 13.14 169 19859 260975 64217729
Muscular weakness 36.22 13.14 104 19924 127234 64351470
Dysuria 35.75 13.14 54 19974 42003 64436701
Migraine 34.11 13.14 66 19962 62611 64416093
Nocturia 33.97 13.14 28 20000 11137 64467567
Arrhythmia 31.61 13.14 58 19970 52886 64425818
Scleral discolouration 31.20 13.14 10 20018 522 64478182
Dementia 30.67 13.14 35 19993 20731 64457973
Multiple sclerosis 29.82 13.14 33 19995 18908 64459796
Delusion 29.42 13.14 32 19996 17982 64460722
Palpitations 28.42 13.14 84 19944 104404 64374300
Prescribed underdose 27.69 13.14 31 19997 17984 64460720
Dizziness 27.17 13.14 227 19801 429936 64048768
Sinonasal obstruction 26.39 13.14 7 20021 186 64478518
Lip disorder 26.09 13.14 11 20017 1250 64477454
Constipation 25.97 13.14 140 19888 229197 64249507
Thrombocytopenia 25.92 13.14 19 20009 223782 64254922
Hypertensive crisis 25.68 13.14 30 19998 18218 64460486
Orthostatic hypotension 23.96 13.14 48 19980 46690 64432014
Hypoaesthesia 23.93 13.14 96 19932 139012 64339692
Balance disorder 23.32 13.14 68 19960 83858 64394846
Idiopathic orbital inflammation 23.28 13.14 6 20022 142 64478562
Feeling drunk 23.05 13.14 15 20013 4152 64474552
Epilepsy 22.94 13.14 39 19989 33492 64445212
Dyskinesia oesophageal 22.66 13.14 5 20023 59 64478645
Cystitis interstitial 20.54 13.14 9 20019 1123 64477581
Infusion related reaction 20.32 13.14 13 20015 164454 64314250
Anal incontinence 19.77 13.14 24 20004 15172 64463532
Pharyngeal mass 19.51 13.14 6 20022 273 64478431
Spinal cord haemorrhage 19.35 13.14 7 20021 528 64478176
Urinary tract disorder 19.01 13.14 12 20016 3154 64475550
Cardio-respiratory arrest 18.44 13.14 4 20024 98389 64380315
Hyperventilation 18.44 13.14 16 20012 6824 64471880
Oesophageal dilatation 18.31 13.14 6 20022 336 64478368
Product blister packaging issue 18.23 13.14 5 20023 151 64478553
Neutropenia 18.13 13.14 29 19999 239595 64239109
Insomnia 17.98 13.14 114 19914 197722 64280982
Therapeutic product effect decreased 17.41 13.14 7 20021 115344 64363360
Bone marrow oedema 17.23 13.14 8 20020 1142 64477562
Contraindicated product administered 17.19 13.14 6 20022 107823 64370881
Hip fracture 16.56 13.14 30 19998 27069 64451635
Amnesia 16.28 13.14 42 19986 48227 64430477
Vascular stenosis 16.20 13.14 6 20022 484 64478220
Treatment failure 16.20 13.14 8 20020 116808 64361896
Persistent genital arousal disorder 16.00 13.14 5 20023 240 64478464
Dropped head syndrome 16.00 13.14 5 20023 240 64478464
Hallucination, visual 15.99 13.14 30 19998 27804 64450900
Maternal exposure during pregnancy 15.87 13.14 5 20023 95879 64382825
Paraesthesia 15.80 13.14 83 19945 134439 64344265
Hypertonic bladder 15.79 13.14 11 20017 3407 64475297
Extradural haematoma 15.71 13.14 10 20018 2666 64476038
Sputum retention 15.56 13.14 7 20021 930 64477774
Perineal pain 15.10 13.14 7 20021 996 64477708
Somatic dysfunction 14.88 13.14 3 20025 22 64478682
Intentional medical device removal by patient 14.85 13.14 5 20023 305 64478399
Abdominal pain upper 14.77 13.14 99 19929 174931 64303773
Product use complaint 14.52 13.14 8 20020 1638 64477066
Stoma site discharge 14.36 13.14 8 20020 1674 64477030
Catheter site injury 14.34 13.14 4 20024 129 64478575
Drug hypersensitivity 14.31 13.14 33 19995 237782 64240922
Rheumatoid arthritis 14.29 13.14 18 20010 164276 64314428
Feeling abnormal 14.06 13.14 80 19948 133522 64345182
Product dose omission issue 14.02 13.14 106 19922 194641 64284063
Atrial fibrillation 13.97 13.14 96 19932 170993 64307711
Open fracture 13.72 13.14 5 20023 385 64478319
Intercepted medication error 13.69 13.14 6 20022 749 64477955
Lip swelling 13.15 13.14 30 19998 31877 64446827

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD12 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058667 Adrenergic beta-3 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185007 Adrenergic beta3-Agonists
FDA EPC N0000185008 beta3-Adrenergic Agonist
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
CHEBI has role CHEBI:35522 beta-adrenergic agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bladder muscle dysfunction - overactive indication 236633002
Hypertensive disorder contraindication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.32 acidic
pKa2 8.7 Basic
pKa3 4.93 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 8835474 Nov. 4, 2023 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL RE44872 Nov. 4, 2023 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 8835474 Nov. 4, 2023 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL RE44872 Nov. 4, 2023 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 8772315 Oct. 30, 2028 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 8772315 Oct. 30, 2028 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 10842780 Sept. 28, 2029 ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL 10842780 Sept. 28, 2029 ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
8MG/ML MYRBETRIQ GRANULES APGDI N213801 March 25, 2021 RX FOR SUSPENSION, EXTENDED RELEASE ORAL 10058536 March 31, 2036 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL March 25, 2024 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL March 25, 2024 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
8MG/ML MYRBETRIQ GRANULES APGDI N213801 March 25, 2021 RX FOR SUSPENSION, EXTENDED RELEASE ORAL March 25, 2024 NEW PRODUCT
25MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL Sept. 25, 2024 PEDIATRIC EXCLUSIVITY
50MG MYRBETRIQ APGDI N202611 June 28, 2012 RX TABLET, EXTENDED RELEASE ORAL Sept. 25, 2024 PEDIATRIC EXCLUSIVITY
8MG/ML MYRBETRIQ GRANULES APGDI N213801 March 25, 2021 RX FOR SUSPENSION, EXTENDED RELEASE ORAL Sept. 25, 2024 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-3 adrenergic receptor GPCR AGONIST EC50 7.65 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D09535 KEGG_DRUG
4031804 VANDF
CHEBI:65349 CHEBI
H6U PDB_CHEM_ID
CHEMBL2095212 ChEMBL_ID
C520025 MESH_SUPPLEMENTAL_RECORD_UI
7445 IUPHAR_LIGAND_ID
8907 INN_ID
DB08893 DRUGBANK_ID
MVR3JL3B2V UNII
9865528 PUBCHEM_CID
1300786 RXNORM
191568 MMSL
28616 MMSL
d07876 MMSL
014540 NDDF
703803006 SNOMEDCT_US
703804000 SNOMEDCT_US
C2983812 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-2601 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-2601 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-2602 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-2602 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-5020 GRANULE, FOR SUSPENSION, EXTENDED RELEASE 8 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 0469-5020 GRANULE, FOR SUSPENSION, EXTENDED RELEASE 8 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 55154-8712 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 55154-8713 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 70518-2435 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL NDA 27 sections
Myrbetriq HUMAN PRESCRIPTION DRUG LABEL 1 70518-3158 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL NDA 27 sections